Xeris Pharmaceuticals Inc. (XERS) Misses Q4 EPS by 3c

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of ($0.41), $0.03 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $7.09 million versus the consensus estimate of $8.21 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• Xeris Biopharma exchanges $23 million in convertible notes for cash and stock